Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Luka BrcicChristian KuchlerSylvia EidenhammerDaniela PabstFranz QuehenbergerAdi F GazdarHelmut PopperPublished in: Diagnostic pathology (2019)
The DLL3 antibody used in the clinical trial demonstrated superiority in the detection of DLL3 expression. Cell cultures, which can be used for DLL3 antibodies as positive and negative probes, were established. Evidence of DLL3 expression in high proportions of patients with LCNEC might provide basis for studies of new therapy options in this group of patients.
Keyphrases
- high grade
- poor prognosis
- clinical trial
- single cell
- end stage renal disease
- cell therapy
- ejection fraction
- chronic kidney disease
- newly diagnosed
- small molecule
- binding protein
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- stem cells
- study protocol
- patient reported outcomes
- single molecule
- open label
- label free
- sensitive detection
- clinical evaluation
- chemotherapy induced